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 The prevalence of pregnancies complicated by chronic kidney disease (CKD) is 
increasing. Yet, CKD in pregnancy tends to be underdiagnosed, as women of 
childbearing age are not regularly screened for renal dysfunction, nor is screening 
incorporated into routine pregnancy follow up. Further, renal dysfunction has significant 
implications for maternal and fetal outcomes, with degree of renal dysfunction at 
conception being the most important prognostic factor. It is established that the risk for 
poorer renal, maternal and fetal outcomes, increases incrementally with severity of CKD, 
with intrauterine death and progression to end-stage renal disease (ESDR) associated 
with severe CKD. However, it is difficult to predict which CKD pregnancies will lead to 
poor outcomes as the definition of CKD in pregnancy is not uniform between studies, nor 
are measurement parameters. This paucity of data prevents the establishment of a 
standard of care protocol and leaves clinicians ill-equipped to care for and manage this 
complex patient cohort. This review discusses renal, maternal and fetal outcomes in CKD 
pregnancies as presented by the literature, in order to demonstrate the contradictions in 
data and gaps in knowledge surrounding this topic, as well as the need for a general 
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Pregnancy and chronic kidney disease (CKD) have a negative reciprocal 
relationship1. One condition antagonizes the other and vice-versa. Pregnancy has the 
ability to exacerbate CKD and impair renal function, while CKD in-turn, can lead to poor 
maternal and fetal outcomes1,2.  Further, there has been the suggestion that there is an 
inverse correlation between the staging of CKD (staged I-V) and pregnancy outcomes2. 
As renal insufficiency increases, renal adaptation to pregnancy becomes markedly 
impaired. Consequently, permanent kidney damage or fetal mortality could ensue. 
However, the aforementioned examples are among extreme outcomes and are more likely 
to occur in women with moderate to severe CKD2. In summary, CKD in pregnancy leads 
to maternal maladaptation, and the primary determinant of pregnancy outcome seems to 
be the degree of renal dysfunction3. 
	 Only a small number of women of childbearing-age are estimated to have 
CKD—approximately 4%3. Yet, as the prevalence of CKD rises in the global population, 
it can be assumed that there will be a growing number of pregnancies in the presence of 
renal insufficiency1,3. Further, this unique patient population is likely to be even more 
numerous given that clinical differentiation between CKD and preeclampsia is 
challenging, and that women are not regularly screened for CKD, as it can present 
asymptomatically3,4. Despite the increase in prevalence, there is not a uniform definition 
of CKD to facilitate evidence-based counseling for pregnant CKD patients3,5. What 
further compounds this issue is that many of the published studies on CKD in pregnancy 
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are not generalizable, as there is a scarcity of large clinical studies across multiple 
centers3,6. A woman who is pregnant while concurrently managing CKD, faces many 
challenges as do the clinicians and care team involved. In the past, pregnancy termination 
was advisable if any level of renal dysfunction was detected during the first trimester 2. 
Today, pregnancy is feasible in all stages of CKD4. However, due to the varying etiology 
of CKD “counseling is imprecise and management varies substantially across centers”6. 
The aim of this review is to discuss renal and pregnancy outcomes, as well as current 
management strategies of pregnant patients with CKD to identify the voids in knowledge 
where future research efforts should be directed in order to improve outcomes for both 
mother and baby.		 
 
Basic Renal Physiology: A Brief Review 
A review of normal renal physiology is essential for the purposes of discussing 
the pathophysiology of CKD in pregnancy. This overview is in no way complete but is 
necessary and sufficient for understanding renal accommodation to pregnancy in the face 
of CKD. The kidney serves the human body in a variety of capacities. It functions as a 
regulatory, excretory and endocrine organ in order to maintain homeostasis7.  
The functional unit of the kidney is the nephron, which is composed of the 
glomerulus and renal tubules. Blood is filtered from the glomerulus into Bowman’s space 
to form ultrafiltrate. The ultrafiltrate is then modified by as it moves through the tubular 
lumen to become urine. At the proximal tubule, there is load dependent glucose, sodium 
and water reabsorption. Here, sodium and water are resorbed isosmotically while 
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potassium absorption is driven by passive diffusion intercellularly. The descending limb 
of Henle’s loop concentrates the filtrate via water reabsorption, while sodium chloride is 
retained in the filtrate. Water movement is driven passively from the tubular lumen by the 
high osmolality of the medullary interstitium. The thick ascending limb of the loop of 
Henle is impermeable to water and dilutes the filtrate by active sodium reabsorption; this 
is also a site of potassium reabsorption. The distal tubule is also a diluting segment—
sodium is reabsorbed while water remains trapped in the tubular lumen. The water 
permeability of the collecting duct is subject to hormone action; vasopressin (ADH) 
increases this segment permeability to water, while in its absence, it is impermeable to 
water. Additionally, the collecting duct contains two different tubular cells, a-intercalated 
and principal cells. The former reabsorbs potassium and secretes hydrogen, while the 
latter secretes potassium and reabsorbs sodium. Urine composition is a product of 
filtration, tubular reabsorption of some solutes and secretion of others; the presence of 
certain substances in the urine such as glucose or protein can be an indication of renal 
pathology.  
The kidneys receive approximately twenty percent of resting cardiac output and 
renal blood flow (RBF) is typically 1 L/min on average8. Blood enters the afferent 
arterioles and moves through the glomerular capillaries, where approximately 20% of the 
plasma (the glomerular filtration rate, GFR) is filtered into Bowman’s space, with the 
remaining plasma flowing through the efferent arterioles and on to the peritubular 
capillaries8. GFR, the volume of plasma per unit time that is filtered across the 
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glomerular filtration barrier1, is one of the hallmarks used to measure renal function. GFR 
is a function of both the permeability of the filtration barrier and Starling forces across 
the glomerulus:  
GFR = Kf (DP-pGC) 
 
where Kf is the permeability of the filtration barrier, that is dependent on the hydraulic 
permeability and the surface area available for filtration9. The ultrafiltration pressure (DP-
pGC) is the difference between glomerular and Bowman’s hydrostatic pressures minus the 
glomerular capillary oncotic pressure (pGC, or pressure due to the presence of proteins). 
The ultrafiltration pressure drives filtration. Changes in the diameter of the afferent and 
efferent arterioles alter the hydrostatic pressure of the glomerular capillaries and thus 
determine renal plasma flow (RPF) and GFR. RBF and GFR are held relatively constant 
over significant changes in renal perfusion pressure; 80 to 200 mm Hg in the healthy 
individual7. This is attributed to the mechanism of autoregulation, which encompasses the 
mechanisms of the myogenic response and tubuloglomerular feedback. The implications 












Table 1: The effects of altering arteriolar resistances on renal plasma flow and 
glomerular filtration rate.  
Adapted from (Costanza 2018)7. *Of note: with constriction of the efferent arteriole, GFR 
initially increases due to an increase in PGC but then eventually falls due to the decrease 








When changes in GFR do occur, glomerulotubular balance (G-T balance) protects against 
excessive salt and water loss or retention. G-T balance guarantees that a constant fraction 
(approximately two-thirds) of the sodium and water that is filtered at the glomerulus is 
reabsorbed at the proximal tubule and prevents significant alterations to body salt and 
water7. Thus, changes to the effective circulating volume (ECV) and the extracellular 
fluid (ECF) are prevented and euvolemia is maintained.  
 Beyond G-T balance, total body sodium is regulated via Starling forces in 
the peritubular capillaries, sympathetic nerve activity, renin-angiotensin-aldosterone 
system (RAAS), and atrial natriuretic peptide (ANP); and assessed by the 
cardiopulmonary receptors, the intrarenal afferent arterioles and baroreceptors in the 
carotid sinus and aortic arch. The baroreceptors sense changes in vascular pressure, 
secondary to an expansion or a contraction of the ECV.  
	 In a hypovolemic state, diminished ECF volume increases capillary 
oncotic pressure and enhances sodium and water reabsorption at the peritubular 
Effect RPF GFR 
Constriction of afferent arteriole ¯ ¯ 
Dilation of afferent arteriole ­ ­ 
Constriction of efferent arteriole ¯ ­* 
Dilation of efferent arteriole ­ ¯ 
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capillaries7. During hypovolemia—an example being hemorrhage—perfusion pressure 
decreases. This is detected by the baroreceptors, which then reduce their firing. 
Sympathetic discharge reciprocally increases, which directly leads to arteriolar 
vasoconstriction, increased proximal tubular sodium reabsorption and upregulation of the 
RAAS10. Renin is produced by the juxtaglomerular apparatus. Diminished afferent 
arteriolar pressure, decreased sodium chloride delivery to the thick ascending limb of 
Henles’s loop (sensed by the macula densa) and augmented sympathetic stimulation leads 
to increased renin secretion10. Elevated levels of renin produce an increase in conversion 
of plasma angiotensinogen to angiotensin I, and its subsequent cleavage into angiotensin 
II (AII) by angiotensin converting enzyme (ACE).  AII acts on many different effectors 
to facilitate a concerted response to recover body sodium and water. AII is a potent 
vasoconstrictor and reduces RBF and GFR , thus diminishing the sodium filtered load10. 
AII stimulates sodium transporters in the proximal tubules, to increase sodium reuptake7. 
In the central nervous system (CNS), AII stimulates thirst, while also stimulating 
vasopressin (or Antidiuretic Hormone, ADH) release. Further, the hormone aldosterone is 
secreted from the adrenal cortex in response to AII. Aldosterone and ADH act to increase 
sodium and water reabsorption in the distal nephron and collecting duct, respectively. 
The roles of aldosterone in potassium balance and ADH in osmoregulation will be 
addressed later in this subsection. Sympathetic nerve activity and the RAAS cascade 
orchestrate an increase in sodium and water retention, thus restoring ECV/ECF7. 
During a hypervolemic state, e.g., when an individual consumes a high sodium 
diet, the ECF and ECV are expanded. In the peritubular capillaries, the oncotic pressure 
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is lower, and sodium and water reabsorption are reduced. In hypervolemia, perfusion 
pressure rises which is sensed by the baroreceptors. Baroreceptor firing increases and 
sympathetic discharge is inhibited. Due to an expanded circulating volume, the atria of 
the heart are expanded to a greater extent with venous return and the cardiac myocytes 
release ANP. The actions of ANP inhibits those of AII and antagonizes the RAA 
System10. ANP increases GFR by selectively vasoconstricting the efferent and 
vasodilating the afferent arterioles7. Thus, the sodium and water filter load is increased. 
Renin, aldosterone and ADH secretion are inhibited. ANP further inhibits sodium 
reabsorption by acting directly on the late distal tubule and collecting duct. There are 
local humoral factors released by the kidney to augment inhibition of sodium resorption 
and compound vasodilation, but for the sake of simplicity, they will not be addressed 
here. Summarily, ANP acts to increase sodium and water excretion by increasing their 
filtration and inhibiting their reabsorption via mechanisms outlined above. Concerted 
neurohumoral responses to changes in the ECF are depicted in the pathways below 




Figure 1: Neurohumoral Responses to Changes in the ECF/ECV Secondary to Body 
Na+ Changes.  
The left side of the figure indicates the neurohumoral response to a decrease in the ECF, 
while the right indicates a response to an increase in the ECF. Note that one side is 




Maintaining potassium homeostasis is critical for life. At rest, many excitable 
cells are most permeable to the potassium ion, therefore this cation dictates the cell 
membrane resting potential. Fluctuations in the concentration of extracellular potassium 
can have severe consequences7. While the majority of body potassium is intracellular, the 
kidney functions to maintain external potassium balance11. Note that extra-renal 
potassium homeostasis will be excluded from this overview. The proximal nephron and 
thick ascending limb of the loop of Henle are responsible for potassium reabsorption, 
while the distal tubule and collecting ducts fine-tune potassium excretion in response to 
the day-to-day fluctuations in plasma potassium levels7. In the distal nephron and 
collecting duct, a-intercalated cells reabsorb potassium while principal cells are 
responsible for the secretion of potassium. Plasma potassium levels and aldosterone are 
the primary regulators of renal potassium excretion. Acute hyperkalemia directly 
stimulates Na+-K+ ATPases of the distal nephron, and leads to increased potassium 
secretion11. Further, an increase in plasma potassium concentration stimulates aldosterone 
secretion. Aldosterone increases the expression of Na+-K+ ATPases and K+ channels in 
the distal nephron and collecting duct, facilitating potassium secretion11. In addition to 
potassium channels, aldosterone also simultaneously increases expression of sodium 
channels; therefore sodium reabsorption and potassium secretion are coupled7. In fact, as 
more Na+ is extruded from the principal cells by the basolateral pumps, K+ enters, which 
increases the driving force for K+ secretion into the tubular lumen. Additional factors 
involved in potassium homeostasis include the distal flow, i.e., the rate of fluid flow 
through the distal tubule and collecting duct. Increased flow rate dilutes the K+ 
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concentration in the distal tubular lumen and increases the driving force for potassium 
secretion, with the opposite effect being decreased K+ secretion when flow rate is 
diminished. In addition, increased flow rate leads to mechanical activation of lumenal 
Ca2+-dependent K+ channels, enhancing K+ permeability and K secretion. 
Renal mechanisms preserve body fluid osmolality in a healthy individual around 
290 mOsm/L via osmoregulation7. Plasma osmolality increases if water from evaporation 
(insensible water loss due to sweating, breathing, talking etc.) is not replaced. This 
increase in plasma osmolality is detected by osmoreceptors of the hypothalamus, which 
can detect minute increases in osmolality7. The osmoreceptors stimulate thirst and ADH 
secretion which lead to increased water intake and reabsorption, respectively. ADH acts 
on principal cells to increase their water permeability and subsequently increase in water 
reabsorption. “As more water is reabsorbed (…) urine osmolality increases and urine 
volume decreases” and plasma osmolality is restored7. With excessive water ingestion, 
the opposite mechanism holds true in which the decrease in plasma osmolality suppresses 
thirst and ADH secretion. The principal cells are less permeable to water and urine of 
greater volume and less osmolality is excreted to raise plasma osmolality to normal 
levels. The ability of the kidneys to concentrate and dilute urine is due to the 
establishment of the medullary osmotic gradient via urea recycling and the counter-
current multiplier, while washout of the gradient is diminished via counter-current 
exchange12.  
The renal system is also paramount to acid-base balance. The kidney functions to 
excrete non-volatile acids from the body and to compensate for any pH fluctuations 
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created in consequence: reabsorption and regeneration of bicarbonate with excretion of 
hydrogen13. A hydrogen ion is secreted into the urine for every bicarbonate reabsorbed at 
and formed in the kidney in order to replenish the bicarbonate stores that are lost during 
buffering14. Hydrogen is excreted in the urine as either a titratable acid or as 
ammonium14. Both the renal and pulmonary system work in tandem to prevent and 
compensate for bodily acid-base shifts.   
 
Renal Accommodation to Pregnancy in Healthy Women 
The pregnant female undergoes renal, circulatory and urinary changes in order to 
accommodate the fetus15. Physically, women can experience both enlargement of the 
kidney and collecting system, respectively hydronephrosis and hydroureter, which may 
occur as early as 6 weeks gestation15. This expansion of the urinary system is secondary 
to increased circulating and interstitial volume16.  
The modification of systemic and renal hemodynamics is quite extensive and 
multifactorial. In early gestation, both the increase in arteriole compliance and systemic 
vasodilation contribute to decreased total peripheral resistance (TPR)17,18. The decrease in 
afterload (diastolic aortic pressure), leads to a subsequent increase in cardiac output by 
approximately 40-50% 2,18. In early gestation, RPF and GFR correspondingly rise, with 
hyperfiltration being “the most notable physiologic adaptation to normal pregnancy 
which clinically presents as a decrease in the serum creatinine”18. The hormonal mediator 
Relaxin, secreted by the placenta, increases renal secretion of vasodilators nitric oxide 
(NO) which augments renal vasodilation of the afferent and efferent arterioles, 
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contributing to the increase in RPF and GFR15. While RPF increases by approximately 
85% by the 2nd trimester, GFR rises by 57% of normal values. Thus, the filtration fraction 
(GFR/RPF) drops from 0.2 to 0.17. Although both, RPF and GFR decrease in the 3rd 
trimester, the FF remains at 0.17. (see table 2) 15, 19. While glomerular hydrostatic 
pressure might remain normal (there is no consensus to whether it changes), glomerular 
oncotic pressure decreases during pregnancy, which promotes the hyperfiltration2. 
Systemic and renal vasodilation during pregnancy are further perpetuated by decreased 
responsiveness to the vasoconstrictor AII, and there is evidence that there are elevated 
levels of  angiotensin-(1-7), a component of the RAAS, during pregnancy, which behaves 
as a counter to AII and acts as a vasodepressor rather than vasoconstrictor.15, 20-21. 
 
Table 2: Hemodynamic changes associated with each trimester of pregnancy in 
women with normal renal function. Values taken from (Davidson, Williams, 2008)22. 
 








(ml/min) 480 841 891 771 
GFR 








0.20 0.18 0.17 0.17 
 
During normal pregnancy the RAAS is activated, even in the face of systemic 
vasodilation. Elevated levels of AII and as a result, aldosterone, are secondary to 
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upregulation of angiotensinogen production due to high levels estrogen supplied initially 
by the corpus luteum and later by the placenta21, 23. Plasma renin rises eight-fold, 
aldosterone ten to twenty-fold, and angiotensin increases four-fold of their prepregnancy 
values2. This potentiates increases in renal retention of sodium and water via mechanisms 
orchestrated by AII and aldosterone described previously. Increased renal reabsorption of 
water and sodium contributes to hypervolemia during pregnancy; typically there is a 50% 
expansion in plasma volume and an increase of 6-8 liters in total body water2, 15, 24.  
Tubular regulation of reabsorption and waste excretion undergoes changes 
throughout gestation. Glucosuria is a common physiological finding associated with 
pregnancy. As glucose is freely filtered at the glomerulus, the increase in the filtered load 
(secondary to the increase in GFR) saturates the glucose-sodium transporters of the 
proximal tubule and glucose is excreted1, 9, 15. Further, hormones and humoral factors 
such as placental lactogen, placental insulinase, cortisol, progesterone, and estrogen 
contribute to elevated plasma glucose and therefore a higher glucose filter load. It is also 
suggested that uric acid excretion rises in early pregnancy due to increased GFR and less 
effective fractional reabsorption at the proximal tubule9. Proteinuria is primarily 
attributed pregnancy-associate antiangiogenic factors that can compromise the integrity 
of the filtration slit between pedicels of the podocytes and lead to increase protein 
filtration and subsequent excretion9, 25. 
 During pregnancy, the body’s “osmostat” is reset, i.e. the threshold for 
stimulation of ADH release and thirst are reduced and plasma osmolality is maintained 
around 270 Mosm/L1-2, 9, 15. Yet, plasma ADH concentration remains normal in spite of 
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the increased secretion. This is thought to be the result of the combination of increased 
osmoreceptor stimulation secondary to arterial underfilling, which is compound by 
elevated levels of  placental hormone relaxin9, 26, 27. Relaxin activates the vasodilating NO 
pathway and low blood pressure can lead to avid secretion of ADH to restore blood 
volume preferentially over osmolality. Further, elimination of ADH rises after mid-
gestation and peaks in the third trimester because of increased levels of vasopressinase 
activity, a placental enzyme that degrades ADH28. While there is a net retention of 
sodium—around 900-1000 mEq gain, plasma sodium decreases by about 4-5 mEq 
(normal values range from 135-145mEq) and physiologic hyponatremia ensues2. 
Deoxycorticosterone and aldosterone promote sodium retention. Contrastingly, ANP and 
progesterone promote sodium filtration and excretion; and “the balance between these 
factors is preferential retention of water over salt and lower osmolality”9. In pregnancy, 
there is a net increase in total body potassium29. Aldosterone stimulation of potassium 
secretion is counteracted by  progesterone; therefore potassium excretion is constant 
throughout pregnancy30.  
 Progesterone, which peaks at the 37 week of gestation, directly stimulates 
the central respiratory center “by increasing the sensitivity of the respiratory centre to 
carbon dioxide”31. Minute ventilation rises, and blood carbon dioxide tension decreases 
to 27-32 mmHg, which precipitates a mild respiratory alkalosis15. Yet blood remains only 
slightly basic at 7.4-7.47 due to increased renal excretion of bicarbonate31. Major renal 






Figure 2: Major renal accommodations to pregnancy.  
Note that these are only some of the more significant changes and is far from complete. 
Figure taken from (Koratala, Bhattacharya, and Kazory, 2017)1. 
 
Defining Chronic Kidney Disease in Pregnancy  
In patients with CKD, renal accommodation to pregnancy can be compromised 
due to the increase in physiologic demands on a kidney already under pathophysiologic 
duress. Before discussing the pathophysiological consequences of CKD in pregnancy and 
their outcomes, it is necessary to establish a working definition of both CKD and CKD in 
pregnancy for the purposes of this review. In 2002, the Kidney Disease Outcomes 
Quality Initiative (KDOQI) established principles to characterize and classify CKD. CKD 
is defined as “having abnormalities of kidney structure or function for at least 3 months 
with implications for the health of the individual”32. Clinically, it is classified according 
to cause, GFR, and albuminuria32. Of note, clinically GFR cannot be measured directly 
but is rather estimated by determining either clearance measurements or serum 
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concentrations of a filtration marker33. Due to convenience, that latter method is more 
commonly used in clinic33. For purposes of simplification, I will more broadly categorize 
CKD based on estimated GFR (eGFR), (See table 3).  Stage 1: is associated with kidney 
damage and either normal to elevated GFR2. Stage 2: damage to the kidney with slightly 
lower GFR2. Stage 3: moderately lower GFR, and divided into two subcategories with 3a 
associated with mildly to moderately decreased GFR, and 3b Moderately to severely 
decreased GFR32. Stage 4: Severely decreased GFR32. Lastly Stage 5: Kidney failure32. In 
pregnancy, CKD exists on a spectrum rather than in explicit categories. Further, “the 
existing literature is contradictory and difficult to synthesize due to the variable means 
used to define the level of CKD that has also changed over time”6. CKD in pregnancy is 
more summarily, if not vaguely categorized into mild, moderate and severe; and is based 
on serum creatinine levels as there is no current, accurate formula for calculating GFR in 
the pregnant individual2 (see table 4). For fluidity, I will group women with stage 1 and 2 
CKD prior to pregnancy into the “mild” category. “Moderate” will include women in 
stage 3, and stage 4 and 5 will be categorize as “severe.” I acknowledge that the spectrum 
from mild to moderate presents a bit of a gray area. I am recategorizing women with 
explicit staging prior to conception into more general categories, for the ease of 







Table 3: Staging of Chronic Kidney Disease based on eGFR   
This table was populated using eGFR values from (Raghavan and Eknoyan, 2014) 32. 
GFR is dependent on body size, in this table it is measured relative to an average surface 








Table 4: Categorization of severity of CKD in pregnancy relative to serum 
creatinine levels.  






Stage GFR (mL/min/1.73m2) 





5 < 15 
Category Serum Creatinine Levels (mg/dL) 
Mild < 1.4  
Moderate 1.4-2.5 
Severe > 2.5 
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Specific Aims  
Pregnancy is characterized by necessary physiological renal adaptations in order 
to orchestrate a healthy and successful outcome for mom and baby. For women with any 
degree of CKD, the physiologic demands of pregnancy may worsen preexisting renal 
dysfunction or unmask undiagnosed renal disease34. Further, this distinctive patient 
population is growing because of increasing prevalence of CKD in the general 
population. However, clinical management can be difficult due to a lack of uniform 
definition of CKD in pregnancy, CKD’s varying etiologies and a scarcity of large and 
generalizable clinical studies. The primary objective of this review is to outline each of 
the classifications of CKD in pregnancy based on current data in the literature, including 
their associated maternal and fetal outcomes. Clinical management strategies will also be 
discussed, including a review of a proposed algorithm. The hope is that this review will 
demonstrate the complexity of managing CKD in pregnancy and determine where future 
research efforts could be directed in order to improve management and pregnancy 





The Effect of CKD on Maternal Renal Accommodation 
 
Can kidneys with CKD accommodate the physiological demands of pregnancy? 
 It is known that renal and systemic hemodynamic alterations associated with 
pregnancy do not readily occur in women with CKD2. There is often reduced expansion 
of plasma volume and the hallmark mid-gestational rise in GFR can be dampened or even 
absent depending on severity of renal dysfunction.22, 35, 36. However, it is critical to note 
that in a multicenter study, Katz found that the typical gestational rise in RPF and GFR 
did occur in pregnancies of women with mild kidney disease, just as these two 
parameters do in normal pregnancies37. In Jones’s and Hayslett’s retrospective study, 
they measured GFR in 70 pregnancies complicated by moderate to severe CKD: In 79% 
of the pregnancies, GFR remained stable, GFR decreased by 25% in 14% of the 
pregnancies, and in 1% of pregnancies, GFR increased by 25%38. During an 18 year 
longitudinal study by Cunningham, “the magnitude of pregnancy-induced hypervolemia 
was correlated with the degree of renal insufficiency”36. This study found that pregnancy-
induced volume expansion in women with moderate CKD was similar to that of normal 
pregnancies; whereas women with severe CKD had significantly reduced hypervolemia36. 
Cunningham demonstrated that the degree of the pregnancy-induced increase in blood 
volume was inversely related to levels of serum creatinine in CKD pregnancies, with high 
creatinine levels (reduced GFR) associated with reduced blood volume expansion when 
compared to pregnancies with low creatinine levels (higher GFR), see Figure 436. 
However, according to Vellanki and Hou, based on their 2020 review of the literature: 
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“while it is widely perceived that pregnancy-induced hemodynamic changes do not 
always occur in women with CKD, to what extent the ‘normal’ physiological changes 
seen in pregnancy are ‘abnormal’ in CKD women is not known”2. Based on the 
aforementioned literature, one can easily conclude that pregnant women with CKD of 
any severity are less likely to produce the normal renal-induced physiological changes 
required of normal pregnancy, but these changes and the extent of these changes has not 





Figure 3: Blood volume expansion and serum creatinine levels during pregnancy.  
As serum creatinine rises (i.e., GFR is reduced), the percentage increase in blood volume 






Pregnancy and Maternal Renal Prognosis 
Mild CKD 
 Mild CKD is typically defined in the literature as serum creatinine less than 1.4 
mg/dL with varying levels of proteinuria. During a review of 906 pregnancies in women 
with mild CKD, 3% of women developed progressive renal dysfunction39. Contrastingly, 
in a study by Piccoli in 2012, there was a small increase in serum creatinine for all 89 
women with mild CKD from the time they were referred to the study (before the 20th 
week of gestation) to the time of delivery40. However, this study did not provide values 
for serum creatinine in the prepregnancy or post-partum periods, which begs the question 
of the significance of this incremental increase in serum creatinine and whether or not 
creatinine levels returned to baseline after delivery. In 2015, the Piccoli’s group 
performed the Torino-Cagliari Observational Study (TOCOS) which examined the 
pregnancy outcomes of 504 women with CKD, 370 of which were identified to have mild 
CKD. They found that 7.6% of the studied women with mild CKD progressed to a more 
advanced stage of CKD, after preganancy41. Yet, in Jungers case-control study, which 
included 360 patients with mild renal impairment, (in the presence of minimal proteinuria 
and absent or controlled hypertension), pregnancy generally had no detrimental effects on 
renal function during pregnancy and after birth 22, 42. In Williams’s and Davison’s review 
of literature from 1985-2007, it was found that “most women with chronic kidney disease 
who become pregnant have mild renal dysfunction and pregnancy does not usually affect 
renal prognosis” 22. This suggests that in women with mild CKD, delivery generally 
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reverses any decline in renal function that occurs during gestation and only a small 
percentage of women have pregnancy-induced progressive renal damage 42.  
  
Moderate to Severe CKD 
Moderate and severe renal dysfunction are characterized by serum creatinine 
ranging from 1.4 mg/dL to 2.5 mg/dL and greater than 2.5 mg/dL, respectively2. It is 
important to note that definitions of moderate and severe CKD vary among studies and 
often overlap. In the literature, the distinction between these two categories is a bit of a 
gray area and the degree of renal impairment is classified more on a continuum rather 
than in discreet categories. This complicates the comparison of renal outcomes between 
studies and prevents evidence-based conclusions from being made or implemented 
clinically. For pregnancies complicated by moderate or severe CKD, there is often a 
continuous decline in renal function even after delivery, although the mechanism of this 
decline is unknown2. In Jones and Hayslett’s study, an estimated 25-38% of women with 
moderate CKD had a marked rise in serum creatinine during pregnancy, which persisted 
in approximately one third of the cohort for about 6 months after birth3,38. As mentioned 
previously, they had reported that women with moderate CKD had a 40% risk of a 
decrease in GFR during pregnancy and 23% of the studied pregnancies progressed to 
end-stage renal disease (ESRD) in the post-partum period6,38. A prospective study on 49 
women diagnosed with stages 3-5 CKD prior to pregnancy demonstrated similar 
findings43. Women with a GFR less than 40 mL/min/1.73m2 and proteinuria greater than 
1 g/24hrs prior to conception had augmented renal dysfunction throughout pregnancy and 
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post-partum6, 22, 43. According to the TOCOS study, in 16.2% of women who had been 
diagnosed with stage 3 CKD prior to pregnancy and in 20% of women with stage 4-5 
CKD, renal dysfunction progressed and the women were diagnosed with a more 
advanced stage of CKD after delivery6, 41. Women with severe CKD at conception have 
the highest risk of accelerated renal dysfunction, with about 25% of this patient 
population predicted to develop ESRD after birth, based on previously studied cohorts 
(see table 5)3,22. “Once a decline in renal function has occurred, it cannot be predictably 
reversed even upon termination of pregnancy”2. To conclude, delivery for women with 
moderate to severe CKD, does not return renal function to prepregnancy baseline; and 
this patient population is more likely to observe a significant decline in renal function 
during pregnancy with long-term renal consequences post-partum including ESRD6.  
 
End-Stage Renal Disease (ESRD) 
Pregnancy in women with ESRD (stage IV of CKD) is less common because 
fertility decreases with a decline in GFR6. “While the exact mechanisms are unclear, 
impaired hypothalamic-pituitary axis from uremia, underlying comorbid conditions 
(anemia, depression), and concomitant medication usage are all thought to be 
contributing factors”2, 44. Improved comprehension of the nutritional and clearance 
requirements of pregnancy in combination with advances in dialysis care, make 
pregnancy more viable for women with ESRD2. It is important to note that no clinical 
trials on ESRD and pregnancy have been performed and that there is limited literature on 
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this patient population. The literature that does exist is from single-centers and is not 
generalizable. There are currently no evidence-based guidelines for clinical management.  
 
As discussed previously in women with mild CKD, only 2% experienced a 
significant loss in renal function during pregnancy, which resolved postpartum. Whereas, 
women with moderate CKD had a significant decline in renal function during pregnancy, 
with dysfunction persisting postpartum for 20% of these women and resulting in ESRD 
for 2%. Lastly, in women with severe CKD nearly half of this group had greater than 




Table 5: Estimated effects of mild to severe CKD on maternal renal function, with 
values being the percentage of women affected in the literature from 1985-2007.  
















<	125	 2	 0	 0	
125-180	 40	 20	 2	




The Relationship Between Degree of CKD and Pregnancy Outcomes 
 
It is well established that the degree of renal dysfunction prior to conception is the 
most important implication for maternal and fetal outcomes. Many studies agree that 
there is an elevated risk of adverse pregnancy outcomes in all stages of CKD and that 
CKD alone without comorbidities is a risk factor for complications. Increases in staging 
of CKD proportionally raises the risk of poor maternal and fetal outcomes, with severe 
CKD and ESRD being associated with the most devastating outcomes for mother and 
baby. It is notable that pregnancy outcomes vary across the literature. This could be 
attributed to a general lack of prepregnancy data for many studies and the use of different 
definitions of GFR and therefore categorization of degree of renal dysfunction. 
Pregnancy in women with CKD commonly induces secondary pathologies such as 
maternal hypertension, proteinuria or preeclampsia, while increasing the risk for fetal 
complications such as placental abnormalities, preterm births, cesarean section, low birth 
weight, intrauterine growth retardation (IUGR), and even neonatal death. This section 
will discuss the types of maternal and fetal pathologies that can develop as a result of 




Common maternal complications of pregnant women with mild CKD include 
increased proteinuria, new-onset hypertension and preeclampsia2. These pathologies can 
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develop in as many as one in three pregnancies with CKD3. However, in a Norwegian 
population study based on the Nord-Trondelag Health Study (HUNT) II cohort, there was 
no increased risk for preeclampsia in women with mild CKD when compared to control 
pregnancies45. This study only provided data regarding hypertension and proteinuria in 
the context of preeclampsia rather than either condition alone. Whereas, the TOCOS 
study (performed more recently), found that 20.5% of women with mild CKD (stage I 
prepregnancy) had an increased risk of either new or developing worsening proteinuria, 
and had a 7.9% increased risk of new-onset hypertension41. Further, in women who were 
categorized as stage 2 CKD, 37.9% of them developed new-onset or doubled proteinuria, 
and 17.6% had new-onset hypertension during pregnancy41.  
 
Fetal Outcomes 
 The risk for cesarean delivery, low birth weight, and prematurity are marginally 
greater in pregnancies with mild CKD than the general population3. It has been found that 
the danger of pregnancy complications increases in patients with mild renal dysfunction 
and whom lack common risk factors such as hypertension or proteinuria41. That is to say, 
even mild CKD alone creates a risk for fetal complications. In Piccoli’s earlier study on 
the Italian cohort, she found that in patients with mild CKD, 46.4% required a C-section, 
28.3% delivered preterm (< 37 week gestation), 14.2% of the infants were small for their 
gestational age (SGA) and 14.2% of them required neonatal intensive care unit (NICU) 
stays40. Her later work with the TOCOS study yielded similar results. Piccoli had noted a 
greater prevalence of preterm deliveries and C-section with utilization of the NICU in 
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women with mild CKD (stages I and II), when compared to the general population40,41. 
However, most studies support the optimistic view that pregnancies with mild CKD have 
successful pregnancy outcomes. “Recent data suggest a successful fetal outcome in 98% 
of pregnancies, while 65% of the pregnancies resulted in no fetal complication” 3, 46. 
Overall, fetal outcomes are good in the face of mild CKD.  
 
Moderate to Severe CKD 
Maternal Outcomes 
 In pregnancies with moderate CKD, proteinuria and hypertension are more 
common concomitants than in pregnancies with mild CKD and oftentimes worsen 
throughout gestation3. Additionally, anemia, chronic hypertension and preeclampsia are 
also among some of the more prevalent complications during pregnancy with moderate 
CKD47. In the 26 pregnancies with moderate CKD that Cunningham studied, he found 
that 73% developed anemia, 62% were complicated by hypertension and 58% had 
preeclampsia36,47. Of the 11 pregnancies that Cunningham observed with severe CKD, 
100% had anemia, 64% were preeclamptic, and 82% had hypertension36, 47. In the more 
recent TOCOS study, women with moderate CKD had a 47.1% increased risk for new-
onset hypertension, and an 86.5% risk of either developing new-onset or doubling 
proteinuria41. These complications were less pronounced in women with severe CKD, but 
not significantly so41. In the HUNT II study, women with severe CKD had increased odds 
of developing preeclampsia (odds ratio of 10.36), while women with moderate CKD did 
not45. Further, women with moderate to severe CKD had greater odds of becoming 
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hypertensive45. While there is some discrepancy in the literature regarding maternal 
outcomes in women with moderate to severe CKD, one can conclude that the risk of 
maternal complications increases incrementally with degree of renal dysfunction at 
conception.   
 
Fetal Outcomes 
Predictably, the risk of adverse fetal outcomes increases with higher degree of 
CKD at conception. In the literature, there are higher rates of preterm births, C-section, 
SGA, use of the NICU and intrauterine deaths. There are also higher reports of excess 
amniotic fluid in the uterus (polyhydramnios) and placental anomalies2. Cunningham 
reported that of the pregnancies with moderate CKD, 35% had intrauterine growth 
retardation (IUGR) and 30% of these women gave birth before term, with 22% delivering 
via C-section36. In the women with severe CKD, 43% experienced SGA, 86% gave birth 
before the 37th week of gestation and 44% had C-sections rather than vaginal births36. 
The TOCOS study confirmed these outcome statistics to an even greater extent. In 
women with moderate CKD, Piccoli observed that 24.3% of infants were SGA, 78.4% of 
deliveries occurred before term with birth on average occurring at the 34.4 (± 2.4) week, 
78.4% of the cohort required C-section deliveries, and 44.4% of infants needed the 
NICU41. In women with severe CKD, 75% of infants were SGA, 88.9% of deliveries 
were preterm, with the average gestational age of 32.6 weeks (± 4.2), 70% of deliveries 
were via C-section and 70% of infants required the NICU41. While the significance of the 
higher rate of C-sections in the moderate CKD cohort is minute, this could be attributed 
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to the difference in cohort size; women with a greater degree of CKD have more 




 In pregnancies with ESRD, hypertension and preeclampsia are the most 
frequently reported maternal complications. Since 1998, it is been accepted that 
approximately 80% of pregnant ESRD patients are hypertensive48. However, incidents of 
concomitant preeclampsia have been more variable2. Other maternal complications 
include anemia, premature rupture of membranes, hemorrhage and maternal death48. 
However, it is notable that presently maternal mortality has been greatly reduced and is 
even considered absent due to advances in obstetric and nephrological care.  
 
Fetal Outcomes 
 The number of live births in women with ESRD has increased from 23% reported 
in the 1980s to 75% in the twenty-first century48. Common fetal complications include 
miscarriage, IUGR, fetal suffering, placental detachment, C-section, polyhydramnios, and 
pre-term birth48. Miscarriage has been reported in 25% of cases before mid-gestation48. 
Fetal malformation occurs in 10% of pregnancies and IUGR occurs more variably, 
affecting 28 to 38% fetuses48. Before the twenty-first century, prematurity and low-birth 
weight occurred in 100% of live-births in women on dialysis. Mean gestational age is 
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currently 32 weeks, but only impacts 83% of live births, with the remaining 17% carrying 
to term48. Better fetal outcomes have been attributed to increasing the frequency of 
dialysis in pregnant women with CKD. When comparing fetal outcomes of the Canadian 
and American ESRD registries, on average Canadian women averaged 43 hours of 
dialysis a week versus American women who averaged just 17 hours6. The higher 
frequency of dialysis was correlated with the 82% of live births in the Canadians, 
whereas Americans had only 53% of live births6. Further, infants of women receiving 
more intense dialysis were carried longer and had higher birth weights6.  
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Management of CKD in Pregnancy 
  
 Pregnancy in women with CKD presents a challenging situation for clinicians. 
While advances in obstetric and nephrological care are increasing the number of 
successful pregnancies, clinical management is complex and there is a lack of evidence-
based guidelines for clinicians. The literature suggests that “women with CKD may 
benefit from a multidisciplinary approach,” which would involve an obstetrician, 
nephrologist and a neonatologist coordinating care1. Preconception planning allows CKD 
patients to be fully informed of the various risks associated with pregnancy and for 
clinicians to optimize outcomes by controlling modifiable variables34. During pregnancy, 
the clinical manifestations of CKD are managed rather than primary diseases22. Lastly, in 
the post-partum period, CKD is managed based on maternal renal outcomes and 
breastfeeding viability22. Not only does the etiology of primary disease often dictate an 
individualized management course, but care varies across centers. A uniform 
management algorithm is called for, which would allow clinicians to navigate care-
management of this complex cohort more easily. In this section will explore how 
clinicians could manage pregnancy in CKD, by combining Fitzpatrick’s and her 








 Even though fertility is reduced with any level of renal dysfunction, discussion 
and education of the patient on contraception use is critical. The options for contraceptive 
methods are dictated by the patient’s primary disease, any comorbidities and potential 
contraindications of usage34. Of note, the effectiveness of different methods of 
contraception are not well documented or known in this patient population34. Fitzpatrick 
has suggested using the United Kingdom’s Royal College of Obstetricians and 
Gynecologists guidelines for contraception in women with comorbidities such as diabetes 
and hypertension, for renal disease as well as no guidelines for contraceptive use in this 
patient population exists. Regardless, “contraceptive measures that consider clinical 
comorbidities should be taken by those who do not wish to become pregnant”22. For 
women who do wish to become pregnant, there should be an evaluation of risk factors, 
blood pressure and primary renal disease should be well stabilized, and a management 
plan should be coordinated34. Patients with heritable primary renal diseases such as 
polycystic kidney disease should be provided the option of genetic counseling34. Primary 
disease and comorbidities require individualized treatment to facilitate conception and a 
successful pregnancy.  The many different etiologies of CKD preclude this review from 
being comprehensive, but specific diseases will be discussed to provide context and 
examples of individualized care in the pre-pregnancy period. Patients with 
glomerulonephritis require sufficient immunosuppression approximately 6 months in 
advance to conception34. In women with polycystic kidney disease or reflux neuropathy 
there should be regular urine surveillance for bacterial growth34. As mentioned 
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previously, a common comorbidity associated with CKD is hypertension and is 
controlled with RAAS antagonists. Drugs that act as teratogens such as the common 
hypertensive drug, Angiotensin converting enzyme inhibitor (ACE inhibitors), are 
stopped before pregnancy or after pregnancy is confirmed22. Aspirin can be administered 
at low doses to reduce preeclampsia and adverse pregnancy outcomes49. Lastly, it is 
advisable that all women with CKD, regardless of stage or etiology, contemplating 
pregnancy should begin a folic acid supplementation as women without CKD would22,34. 
 
Peripartum management 
 Antenatal maternal care should be directed towards measures of decline in kidney 
function, blood pressure, urine monitoring, proteinuria and ultrasound to monitor for 
urological obstruction (these parameters are outlined below in table 6)22. Pregnancy 
monitoring and CKD management must be individually tailored to severity and etiology 
of the patient’s CKD. Regardless of etiology, the Fitzpatrick algorithm suggests that 
CKD pregnancies should be monitored with monthly measurements of renal function, 
proteinuria and immunosuppressive levels. Blood pressure should be measured weekly 
and screening for bacteriuria should occur with the onset of each trimester. Management 
of the more common risk factors of hypertension, proteinuria and preeclampsia in CKD 








Table 6: Parameters clinicians are advised to measure for CKD pregnancies.  





1) Every 4-6 wks review for infection 
2) Measure for proteinuria  
3) Hematuria 
Blood Pressure Check regularly, optimal range 120/70 mm Hg to 140/90 mm Hg 
Renal function Serum creatinine and urea 
Ultrasound of renal tract Advised baseline and again at 12 wks 
 
As mentioned previously, “hypertension is an additive risk factor at all stages of 
CKD” in pregnancy34,41. However, there is minimal data discussing blood pressure 
management guidelines for CKD pregnancies. Commonly prescribed antihypertensive 
drugs are not safe in pregnancy as they can readily cross the placenta and lead to fetal 
complications2. Many first-line pregnancy-safe antihypertensive drugs have not been 
formally studied in human CKD cohorts but are generally used in CKD pregnancies that 
require hypertensive treatment6. 
Worsening proteinuria in CKD pregnancies is associated with adverse maternal 
and fetal outcomes, and is relevant measure for risk stratification41. Prophylaxis for and 
proteinuria management in CKD pregnancies depends on primary renal disease and data 
regarding this topic is sparse. However, proteinuria is commonly associated with 
nephrotic syndrome, and is a sign of waste excretion and nutrient absorption compromise 
at the level of the kidney. Thromboembolism incidence occurs commonly with nephrotic 
syndrome50. Thus, it has been suggested that treatment with an immunosuppressant or 
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dosing of heparin maybe warranted if a pregnant CKD patient is suspicious for nephrotic 
syndrome34.  
 Differentiating between preeclampsia and worsening renal dysfunction can be 
quite difficult as they present with similar features4. Features of both pathologies include 
worsening proteinuria and hypertension34. An incorrect diagnosis of preeclampsia could 
lead to prematurity by unnecessary delivery, while failure to diagnose preeclampsia could 
advance maternal renal function decline6. The literature suggests differentiating via 
doppler examination, platelet count, or measurements of various biomarkers such as 
placental growth factor or placental proteins6, 34. However, it is important to note that 
these biomarkers are not readily available but could be an important diagnostic tool in 
future. For the time being, it is recommended that pregnancies in CKD with preeclampsia 
be managed similarly to non-CKD preeclamptic pregnancies, with emphasis on blood 
pressure control and maintaining renal function34. 
The literature suggests that fetal surveillance in CKD pregnancies should be more 
frequent and thorough than that of normal pregnancies. There should be ultrasound 
measurements of amniotic fluid volume and fetal growth; during 28-30 week gestation 
there should be doppler examination of critical vessels and the fetal heart34. 
Cardiotocography should be used at 28 weeks to assess fetal heartbeat; if fetal distress is 







	 It can take over three months in normal pregnancy for the physiological 
adaptations to resolve22. In CKD pregnancies, resolution of the physiological changes can 
be prolonged or even permanent depending on whether renal function is restored to 
prepregnancy baseline. It is suggested that “during that time, close monitoring of fluid 
balance, renal function, blood pressure and a further review of drug treatment are 
necessary”22. The general school of thought regarding breastfeeding is that benefits 
outweigh the risks. Certain immunosuppressant drugs can be detected in breastmilk but it 
is not apparent whether infants absorb them22. Pregnancy-safe hypertensive drugs are 






Figure 4: Fitzpatrick et al proposed general algorithm to guide clinical management 
of CKD pregnancies.  
Taken from (Fitzpatrick, Mohammadi, Jesudason, 2016)34. 
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A Need for Increased Awareness 
 
Defining CKD in pregnancy revisited 
 As previously mentioned, CKD in pregnancy lacks a uniform definition across the 
literature. This makes comparing and contrasting results and outcomes between studies 
exceedingly difficult. For instance, in the 2015 TOCAS study, CKD in pregnancy was 
categorized as it is prior to pregnancy: using the traditional CKD Staging I-V based on 
GFR41. Whereas other authors, such as Bili in 2013 and then Vellanki and Hou in 2020 
use mild, moderate and severe categorizations based on serum creatinine levels2,3. In 
Piccoi’s 2011 review of the literature from 2000-2009,  it was evident from the 26 studies 
that were compared that: “Definitions of diseases, outcomes and stratifications were 
nonhomogeneous, thus impairing meta-analytic pooling and quantification of the risks”5. 
The absence of a consistent definition prevents international comparisons of the maternal 
and fetal outcomes, as well as care and management strategies. Multicenter and cross-
disciplinary collaboration is called for to establish a working definition and create a 
standard-of-care protocol for CKD in pregnancy that can be applied clinically. 
 
A growing prevalence  
 From an epidemiological stand point, CKD in pregnancy is rare. Significant renal 
dysfunction typically affects older, post-menopausal women, rather than those who are in 
their childbearing years3,51. Therefore, women who are pregnant are not regularly 
screened for renal insufficiency because this age population is not commonly affected by 
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renal dysfunction and screening for CKD is not included in routine care of a pregnant 
woman3,40.  Additional rationale which impairs the early diagnosing of CKD is the 
“physiological increase in the renal clearances from the early stages of pregnancy and the 
clinical and laboratory overlap with preeclampsia”40. Preeclampsia is defined as new-
onset hypertension with proteinuria and signs of other organ damage, which typically 
occurs after 20 weeks of gestation2. This definition is strikingly similar to moderate-
severe CKD, and tests need to be more readily available for centers to differentiate 
between the two. Thus, it is acknowledged that the prevalence of CKD is believed to be 
higher than the reported 3-4% in women of child-bearing age. If the size of this cohort 
were adequately accounted for, perhaps more investment and research would be directed 
toward management and outcomes. Further, this patient population is expected to grow in 
numbers as CKD prevalence increases in the general population and standard obstetric 
care teams are not necessarily equipped with the required nephrotic knowledge to manage 
such complex care.  
 
Paucity of Data 
 The lack of data can be attributed to both the heterogenous definition of CKD in 
pregnancy and that this condition does not generally affect pregnant women. While there 
have been a few multicenter studies of CKD in pregnancy in the twenty-first century, 
their results have been somewhat contradictory which questions the validity and strength 
of their conclusions.  Based on these studies, we are unable to predict which women will 
advance renal dysfunction if they proceed with pregnancy and if they will experience 
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pregnancy complications or adverse pregnancy outcomes. Further, the majority of the 
studies that are performed are from single-centers and are retrospective with limited pre-
conception and postpartum data and are therefore not generalizable3.  This scarcity of 
data is felt at the level of clinical practice, where physicians and care team providers are 




It is established that pregnancy and renal disease antagonize one another. Renal 
dysfunction blunts normal maternal accommodation to pregnancy, while the 
physiological demands of pregnancy can exacerbate renal dysfunction. It is known that 
the pregnancy-induced hypervolemia and systemic and renal hemodynamics are impaired 
in the face of CKD, but whether all of the renal-driven physiological adaptations to 
pregnancy occur has yet to be elucidated in the literature. Prior studies have suggested 
that CKD alone increases the likelihood of pregnancy complications and adverse 
pregnancy outcomes. Further, degree of renal insufficiency prior to conception is 
positively correlated with level and frequency of maternal renal prognosis, maternal 
outcomes and fetal outcomes. However, due to inconsistencies in defining CKD in 
pregnancy, variability of measured research parameters and even research results, 
predicting which patients will have adverse outcomes is difficult to say with certainty.  
These difficulties transcend beyond the research, leaving clinicians ill-prepared to care 
for a patient with such a complex intersectionality of disease. It is predicted that more and 
more pregnant women will be affected by CKD if more early diagnoses are made, as such 
a standard of care protocol is warranted. This could be achieved if there was a uniform 
definition of CKD in pregnancy, enabling easy comparisons of past and current studies 
and allow researchers to draw evidence-based conclusions. In general, more studies need 
to be performed with similar measurements and parameters, facilitating more concrete 
conclusions and generalizations. Regardless of where we are at in the research, CKD 
pregnancies should always be classified as CKD pregnancies and a multidisciplinary 
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team consisting of a nephrologist, neonatologist and obstetrician should be managing 
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